Rigel Pharmaceuticals partner Kissei files NDA in Japan for olutasidenib to treat relapsed AML

Rigel Pharmaceuticals partner Kissei files NDA in Japan for olutasidenib to treat relapsed AML
Rigel Pharmaceuticals partner files NDA in Japan

Rigel Pharmaceuticals announced that its partner Kissei has submitted a New Drug Application (NDA) in Japan for olutasidenib, aimed at treating relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation.

The NDA submission marks a significant milestone in expanding olutasidenib access for Japanese patients with limited treatment options. Analysts are watching the regulatory review closely for potential commercial impact should approval be granted.

Rigel Pharmaceuticals recently signed a global license agreement to develop, manufacture and commercialize VEPPANU (vepdegestrant). The company is also scheduled to release its first-quarter 2026 financial results and provide a business update on May 5 2026. These developments come as Rigel continues to expand its pipeline and commercial activities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.